A sequencing report is a document that translates raw genetic data into clinically meaningful categories, and understanding what each section tells you starts with knowing that variants are classified on a five-tier scale from harmless to disease-causing. Most people receiving results for the first time find a mix of clearly labeled findings and frustratingly ambiguous ones, and the difference between interpreting those categories well and misreading them can shape medical decisions for years. The challenge is less about the genetics itself and more about understanding what the report can and cannot tell you with confidence.
The Five-Tier Classification System
Almost every clinical sequencing report in use today classifies genetic variants using a framework developed by the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). This system uses a quantitative, evidence-based scoring approach that places each variant into one of five categories: pathogenic, likely pathogenic, variant of uncertain significance (VUS), likely benign, and benign.1Genetics in Medicine. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen) The classification is meant to separate the evidence for the variant’s role in disease from what that variant means for you personally, and that distinction matters more than most people realize.
When a report says a variant is “pathogenic,” it means there is strong evidence that the variant disrupts gene function in a way linked to disease. “Likely pathogenic” means the evidence points strongly in the same direction but doesn’t quite meet the full threshold. At the other end, “benign” and “likely benign” mean the variant is almost certainly harmless. The middle category, VUS, is the one that causes the most confusion and anxiety, and it deserves its own discussion.
What a Variant of Uncertain Significance Actually Means
A VUS is not a diagnosis. It is not even a soft diagnosis. It means the laboratories and databases that evaluate genetic variants do not yet have enough information to decide whether this particular change in your DNA matters or not. For many people, seeing “uncertain significance” on a medical report triggers real worry, but the honest reality is that most VUS results, when they are eventually resolved, turn out to be benign.
A large study tracking over half a million unique VUS results found that when reclassification happened, roughly 80% of those variants were downgraded to benign or likely benign, while about 20% were upgraded to pathogenic or likely pathogenic. The average time between the original VUS classification and reclassification was about two and a half years for variants eventually called benign and a bit under two years for those upgraded to pathogenic.2JAMA Network Open. Rates and Classification of Variants of Uncertain Significance in Hereditary Disease Genetic Testing In a smaller study focused on hereditary breast and ovarian cancer, about a third of VUS results were reclassified on reassessment, but only a small fraction of those turned out to be pathogenic.3PubMed Central. The Frequency and Reclassification of Variants Uncertain Significance in Hereditary Breast and Ovarian Cancer Among Levantine Patients
The practical takeaway: if your report contains a VUS, your doctor should not be making major medical decisions based on it. Instead, the standard approach is periodic re-evaluation as new data emerge. Laboratories accumulate more population-level data, more functional studies are published, and classifications get updated. You or your clinician can request a re-review down the line, and your genetic counselor can help you understand the timeline and what to watch for.
Why a Pathogenic Variant Does Not Always Mean You Will Get Sick
One of the most common misunderstandings in reading a sequencing report is treating “pathogenic variant found” as equivalent to a disease diagnosis. In genetics, the relationship between carrying a variant and developing symptoms is described by two concepts: penetrance (whether the variant causes any noticeable effect at all) and expressivity (how severe or varied those effects are among people who do show symptoms).
Research using large population datasets has consistently shown that penetrance estimates from early clinical studies were often inflated. Those original studies typically looked at families who already had the disease, which biases the numbers upward. When the same variants are examined in broader population cohorts, penetrance turns out to be lower, sometimes dramatically so. One study examining over 77,000 exomes found that penetrance was 60% or lower for most monogenic metabolic conditions, and expressivity varied widely even among people carrying the same well-established disease variant.4Nature Communications. Determinants of penetrance and variable expressivity in monogenic metabolic conditions across 77,184 exomes A broader review confirmed that many variants once considered fully penetrant look very different in general-population data.5PubMed Central. Incomplete Penetrance and Variable Expressivity: From Clinical Studies to Population Cohorts
This has direct implications for how you read your report. If a pathogenic variant was found because you were tested due to symptoms or a strong family history, the prior probability that it explains your situation is relatively high. If the same variant was discovered incidentally during broad screening with no personal or family history of the condition, the odds that you’ll develop full-blown disease are often considerably lower. A good genetic counselor will frame findings differently depending on this context.
Quality Metrics That Affect How Much You Can Trust Your Results
Not all sequencing results are created equal, and some of the most important information on a report lives in the technical details that most people skip over. Coverage depth is the single most critical quality metric. It tells you how many times each position in your DNA was independently read by the sequencing machine. More reads at a given position means more confidence that any variant detected there is real and not a sequencing error.
For clinical cancer diagnostics where the goal is to detect mutations present in a small fraction of cells, recommended minimum coverage can be very high. One analysis recommended a minimum depth of 1,650 reads together with at least 30 reads showing the mutant version to reliably detect mutations present in 3% or more of cells, because lower coverage risks both missing real mutations and calling false ones.6PubMed Central. Standardization of Sequencing Coverage Depth in NGS: Recommendation for Detection of Clonal and Subclonal Mutations in Cancer Diagnostics For standard germline testing, where you’re looking for variants present in roughly half your DNA (because you inherited one copy from each parent), the thresholds are lower. Research has shown that sensitivity reaches 99% at coverage depths in the range of 20 to 40 reads per site, depending on the quality of each individual read.7Nucleic Acids Research. Novel bioinformatics quality control metric for next-generation sequencing experiments in the clinical context
If your report includes a quality summary or metrics page, check whether specific genes or regions had low coverage. A variant call in a region with very low coverage is less reliable. Conversely, a “no variants found” result in a region with inadequate coverage doesn’t actually mean there’s nothing there; the test just didn’t look hard enough.
The Reference Genome and Why It Matters
Every sequencing analysis compares your DNA to a reference genome, which is essentially a standardized map of human DNA. The version of that map matters more than most people realize. For years the standard reference was GRCh37 (also called hg19), followed by an update called GRCh38. More recently, a complete telomere-to-telomere reference (called T2T-CHM13) added nearly 200 million base pairs of previously missing sequence, corrected thousands of structural errors, and opened up the most complex regions of the genome for analysis.8PubMed Central. A complete reference genome improves analysis of human genetic variation
Each reference upgrade has reduced false positives. The T2T-CHM13 reference eliminated tens of thousands of spurious variant calls per sample, including reducing false positives in hundreds of medically relevant genes by up to a factor of 12.8PubMed Central. A complete reference genome improves analysis of human genetic variation Some of the biggest improvements came in regions with duplicated sequences and areas that older references handled poorly.9Nature Communications. The GIAB genomic stratifications resource for human reference genomes Most clinical labs are still transitioning between reference versions, so it’s worth knowing which one your report was analyzed against, particularly if a finding sits in a complex genomic region.
Secondary Findings You Did Not Ask For
If you had exome or genome sequencing, your report may include a section on “secondary findings” or “incidental findings.” These are variants in genes unrelated to the reason you were tested but that have established medical significance. The ACMG maintains a curated list of genes that laboratories are recommended to screen for and report on when found, regardless of the original testing indication. The list is designed to identify genetic risks for conditions where early intervention can prevent serious harm.10Genetics in Medicine. ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing
The list has grown over time. Version 3.0 contained 73 genes, and subsequent updates have expanded it further.11Genetics in Medicine. ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing These genes cover conditions like hereditary cancer syndromes, cardiac conditions that increase risk of sudden death, and metabolic disorders. You typically have the option to opt out of receiving secondary findings before testing, but many people choose to receive them. If your report includes secondary findings, the same penetrance caveats described earlier apply: a pathogenic variant found incidentally, without a family history to support it, carries different prognostic weight than one found during targeted investigation.
Somatic Versus Germline Variants
If your sequencing was done in the context of cancer, your report distinguishes between somatic variants (mutations that arose in your tumor and are not inherited) and germline variants (mutations present in every cell of your body that you were born with). This distinction matters enormously. A somatic variant in a cancer gene might guide treatment decisions for your tumor but has no implications for your children or siblings. A germline variant, on the other hand, could indicate a hereditary cancer predisposition that family members may share.
Distinguishing the two is not always straightforward, especially when only the tumor is sequenced without a matched normal (non-tumor) tissue sample. Computational tools have gotten increasingly accurate at predicting whether a variant is somatic or germline by modeling factors like the variant’s frequency in the sequencing data, tumor content, and local copy number changes. One such approach correctly predicted the origin of 95–99% of variants.12PLOS Computational Biology. A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal Still, clinical guidelines suggest that suspected germline findings from tumor-only testing should be confirmed with dedicated germline testing, particularly when a strong family history is present or the patient was diagnosed at an unusually young age.13PubMed Central. Identifying potential germline variants from sequencing hematopoietic malignancies
Direct-to-Consumer Results Versus Clinical Reports
If your sequencing results came from a direct-to-consumer (DTC) company rather than a clinical laboratory, the reliability picture changes substantially. A study that compared raw DTC data against clinical-grade confirmation testing found that about 40% of variants flagged in DTC raw data were false positives. Some variants that DTC services or third-party interpretation tools classified as conferring “increased risk” were found to be common, benign variants when assessed by clinical laboratories and population databases.14Genetics in Medicine. False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care
This does not mean DTC testing is worthless, but it means any concerning finding from a DTC service should be confirmed through a clinical laboratory before you or your doctor act on it. Clinical labs operate under stricter regulatory oversight, use higher coverage depths, and apply more rigorous variant-calling pipelines. They are also required to validate their tests analytically, though the degree to which clinical validation is independently reviewed has drawn scrutiny. The FDA has noted that routine lab inspections typically focus on whether the test accurately detects the target molecule rather than on whether the test accurately predicts a clinical condition.15Laboratory Medicine. A High-Level Overview of the Regulations Surrounding a Clinical Laboratory and Upcoming Regulatory Challenges for Laboratory Developed Tests
Polygenic Risk Scores and Their Limitations
Some reports include polygenic risk scores (PRS), which aggregate the tiny effects of many common variants across the genome to estimate your relative risk for conditions like heart disease, diabetes, or certain cancers. Unlike single-gene findings that say “you carry variant X in gene Y,” a PRS gives you a percentile or risk category based on the cumulative weight of hundreds or thousands of variants.
The major caveat with PRS is that their accuracy depends heavily on ancestry. Most of the large genetic studies used to build these scores were conducted in populations of European descent, which means PRS are substantially less predictive for people of other ancestries.16PubMed Central. Clinical use of current polygenic risk scores may exacerbate health disparities Researchers have described this as an inescapable consequence of biased study populations, and considerable effort is now going into developing methods that transfer PRS predictions more equitably across global populations.17PubMed Central. Principles and methods for transferring polygenic risk scores across global populations If your report includes a PRS and your ancestry is not primarily European, treat the specific percentile with extra caution and discuss it with a clinician who understands these limitations.
Pharmacogenomics Results
Pharmacogenomics, sometimes abbreviated PGx, is the part of your report that tells you how your genetic makeup may affect your response to certain medications. These results are often reported using “star allele” notation, where each gene variant gets a label like *1, *2, *17, and so on. Your combination of star alleles for a particular gene (your diplotype) is then translated into a predicted metabolizer status: poor, intermediate, normal, rapid, or ultrarapid.
This sounds straightforward, but the naming system is an active source of confusion even among experts. The traditional approach assigns star alleles based on known combinations of variants traveling together on the same chromosome, but sequencing has revealed that a large fraction of the star alleles found in real populations don’t fit neatly into the established groupings. One analysis found that about 41% of star alleles in a global dataset were driven by single rare variants rather than the traditional multi-variant combinations the system was designed around.18PubMed Central. Contradiction in Star-Allele Nomenclature of Pharmacogenes between Common Haplotypes and Rare Variantsa> For practical purposes, this means pharmacogenomic results are most reliable for the well-studied common variants and less certain for rarer ones. If your PGx report recommends a dose adjustment for a medication you’re taking, discuss it with your prescriber rather than changing doses on your own.
What Standard Sequencing Can Miss
Most clinical sequencing today uses short-read technology, which works by breaking your DNA into small fragments and reading each one. This approach is excellent for detecting single-letter changes and small insertions or deletions but struggles with larger structural rearrangements, repetitive sequences, and genes that have near-identical copies elsewhere in the genome. Long-read sequencing technologies have recently advanced to the point where they can accurately find structural variants throughout the genome, including in previously unreachable areas like repetitive sequences and segmental duplications.19PubMed Central. Long-Read Sequencing and Structural Variant Detection: Unlocking the Hidden Genome in Rare Genetic Disorders One validation study using Oxford Nanopore long-read technology detected all tested repeat expansions, structural variants, and variants in genes with highly similar pseudogenes with 100% concordance.20Frontiers in Genetics. Validation of a comprehensive long-read sequencing platform for broad clinical genetic diagnosis
If your short-read sequencing report comes back negative but clinical suspicion for a genetic condition remains strong, it’s worth asking whether long-read sequencing or supplemental testing could pick up what was missed. This is especially relevant for conditions caused by repeat expansions (like Huntington disease or fragile X syndrome) or large deletions and duplications.
Mosaicism and Low-Level Variants
Standard sequencing reports assume that a variant is either present in all your cells (germline) or not there at all. But some variants exist in only a fraction of cells, a phenomenon called mosaicism. This can happen when a mutation arises after fertilization during early development, so only some cell lineages carry it. Low-grade mosaicism, where fewer than 5% of cells carry the variant, is especially hard to detect and requires very high coverage depths to catch reliably.21PubMed Central. Unrevealed mosaicism in the next-generation sequencing era Conversely, high-grade mosaicism, where 70% or more of cells carry the variant, often goes unrecognized because it looks almost like a standard inherited finding.
Mosaicism has practical implications for family planning. If a parent carries a mosaic variant in their germ cells (eggs or sperm), they may pass the variant to a child even if standard blood testing shows them as negative. Parental testing by sequencing can detect germline mosaicism at levels that older methods like Sanger sequencing cannot. One study found that Sanger sequencing could only detect mosaic variants present in 8% or more of reads, while newer sequencing methods picked up lower-level mosaicism that would otherwise be invisible.22The Journal of Molecular Diagnostics. The Value of Parental Testing by Next-Generation Sequencing Includes the Detection of Germline Mosaicism
Mitochondrial DNA Findings
Your report may also include findings from mitochondrial DNA (mtDNA), which is inherited exclusively from your mother and has its own set of disease-associated variants. Mitochondrial variants can exist in a state called heteroplasmy, where some copies of your mitochondrial genome carry the variant and others don’t. The percentage of molecules carrying a given variant affects both disease severity and the reliability of detection.
Detecting low-level heteroplasmy is technically challenging. Long-read nanopore sequencing can detect heteroplasmy as low as 3%, but detection at those levels is unreliable. In one study, the threshold for 95% confident detection was around 12% heteroplasmy, and 90% reliability was achieved only above 21% heteroplasmy with adequate coverage depth.23Scientific Reports. The quality and detection limits of mitochondrial heteroplasmy by long read nanopore sequencing The bioinformatics approach used to analyze mtDNA also matters. How the data are aligned and which reference is used can substantially affect how accurately heteroplasmy is measured, particularly in certain regions of the mitochondrial genome.24PubMed Central. Assessing mitochondrial heteroplasmy using next generation sequencing: A note of caution If your report includes a mitochondrial heteroplasmy percentage, treat it as an estimate rather than a precise measurement, especially at low levels.
DNA Methylation as an Emerging Diagnostic Layer
A newer type of finding that may appear on some reports involves DNA methylation patterns, sometimes called “episignatures.” Rather than looking at your DNA sequence itself, this testing examines chemical modifications on top of the DNA that affect how genes are turned on and off. Certain genetic conditions leave a characteristic methylation fingerprint, and matching your pattern against a database of known signatures can confirm or rule out a diagnosis.
This is especially useful for resolving VUS results. In one clinical study, episignature testing was positive for 18% of VUS cases tested in a targeted analysis, helping to determine whether those uncertain variants were actually causing disease.25European Journal of Human Genetics. Clinical utility of DNA-methylation signatures in routine diagnostics for neurodevelopmental disorders In pediatric epilepsy cases, episignature analysis helped validate pathogenic variants and, in one instance, reclassified a VUS as likely benign when the patient did not match the expected methylation pattern for the associated condition.26Nature Communications. Diagnostic utility of DNA methylation analysis in genetically unsolved pediatric epilepsies and CHD2 episignature refinement Methylation testing is not yet standard on most sequencing reports, but it is increasingly being offered as a complementary tool when sequence-level analysis alone hasn’t provided a clear answer.
The Role of Genetic Counseling in Making Sense of Results
Reading a report yourself can give you a general sense of what was found, but the evidence is clear that professional interpretation substantially improves understanding. A randomized trial found that patients who received in-person genomic counseling had meaningfully better comprehension of what their genetic risk variants actually meant compared to those who only accessed results through a web portal.27PubMed Central. Outcomes of a Randomized Controlled Trial of Genomic Counseling for Patients Receiving Personalized and Actionable Complex Disease Reports Interestingly, counseling also led patients to lower their estimates of how much genetics alone determined their disease risk, which is generally a more accurate perspective for complex conditions.
In a separate study of patients receiving whole-genome sequencing results, satisfaction with the disclosure process was high, but there was a notable gap between what patients expected before testing and what they felt afterward. Before testing, 87% expected the results would influence medical decision-making, but only 54% reported that it had six months later. Similarly, 73% expected the results to influence medication choices, but only 32% felt that had happened.28Genetics in Medicine. Patient understanding of, satisfaction with, and perceived utility of whole-genome sequencing: findings from the MedSeq Project This expectation gap is worth keeping in mind as you approach your own report. Sequencing often provides useful information, but the proportion of results that directly change treatment decisions right away is smaller than most people anticipate.
Privacy and the Identifiability of Genetic Data
Your sequencing report contains information that is, by its nature, uniquely identifying. Unlike a blood test result, which is just a number that could belong to anyone, a genome sequence is essentially a biological fingerprint. Even when genetic data are stripped of names and other identifying information, the technical reality is that re-identification remains possible.29Journal of Law and the Biosciences. The law of genetic privacy: applications, implications, and limitations Genetic data can also reveal information about biological relatives who never consented to testing, including unexpected family relationships. Clinical genetic tests have, in some cases, incidentally detected consanguinity or misattributed parentage, raising complex ethical questions that go beyond the medical findings themselves.30PubMed Central. Institutional protocol to manage consanguinity detected by genetic testing in pregnancy in a minor
Before testing, it is worth understanding who will have access to your results, whether the data will be stored and for how long, and whether it could be used for research. In the United States, the Genetic Information Nondiscrimination Act (GINA) provides some protection against discrimination by health insurers and employers, but it does not cover life insurance, disability insurance, or long-term care insurance. If you’re using a DTC service, read the data-sharing policies carefully. Some companies share aggregated or de-identified data with third parties, and as noted above, de-identification of genetic data is not a guaranteed shield.